A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections

Table 5 Faecal concentrations of SMT19969 following multiple oral doses (Part 2)

Group	Dose	Mean (min – max) Faecal concentrations (μg/g)
		Nominal day of dosing
		Day 5	Day 10
G	200 mg twice daily	1,466 (847 – 2,390)	1,364 (783 – 1,980)
H	500 mg twice daily	2,084 (994 – 3,790)	3,318 (2,130 – 4,970)

ISSN: 1471-2334